Navigation Links
Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
Date:7/30/2009

to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1 / 2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the Company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

TRBN-G

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
11. Trubion Announces Presentations at Upcoming Investor Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , METTLER TOLEDO recentl...nt a free webinar, “The Role of Process Anal...en Engineering” on December 1, 2009. , ...uring the The Role of Process Analytical Technolo...Webinar on December 1, Process Analytical Technol...
(Date:11/19/2009)... , , BLAUVELT, N.Y., Nov. 19 /PRNewswire/ ...wheat germ extract, responds to a press release is...g the Hungarian company for making false and self-...can BioSciences. ,, Dr. Hidvegi stated from hi...rma claim that research on Avemar does not apply t...
(Date:11/19/2009)... , , MALVERN, Pa. and WALTHAM, Mass., ...s (AMR) and Decision Resources find that the leadi...eumonia in Europe is broad-spectrum activity again...to the variety of organisms that can cause nosocom... that they look primarily for agents that provide ...
(Date:11/19/2009)... , World,s Top Gene Synth...onsortium (IGSC) to Coordinate Best Practices in R...0 Percent of Worldwide Gene Synthesis Capacity , ...-- Five of the world’s leading gene synthesi...ll apply a common screening protocol to promote bi...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...versity, Military and Campus Recruitment, and Empl...lobal VP of Recruitment Operations and Diversity ...ober 20, 2008 -- Pierpoint International is please...ice President of Recruitment Operations and Divers...ffing and Diversity for USAA, and previously as Wo...
...Therapeutics,Inc. (Nasdaq: TPTX ) today announced...ts in a Phase I multiple dose clinical trial of NG...t candidate, tezampanel. The trial is,designed to ...tics of,NGX426 when given once daily for five cons...to more than 150 healthy adults in single doses fr...
...n-Small Cell Lung Cancer Enrolled in, First Stage ...boplatin and Paclitax...uticals, Inc. (Nasdaq: PPHM ), a clinical stage b...ibodies for cancer and serious viral,infections, t... the first,stage of its Phase II trial evaluating ...
Other Biology Technology:Robert Cantu Appointed Vice President of Pierpoint International 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial 4
(Date:11/19/2009)...SON This week, scientists are revealing the genet...cereal crops. Corn, or maize, has one of the most ...rsity of Wisconsin-Madison genomicist David Schwar...ticle in the journal Science . , "The maize gen...dead-ends that have troubled would-be sequencers f...
(Date:11/19/2009)... it comes to corn, 1 + 1 = more than 2: The offspr...oth of their parents. Characterizing the gene-leve... as heterosis or hybrid vigor, could boost our abi...uch as high protein content for human consumption ...h help from the newly released DNA sequence of the...
(Date:11/19/2009)... massive survey of genetic diversity in maize, als...tes, have developed a gene map that should pave th...is a major source of food, fuel, animal feed and f...type of gene map known as a haplotype map, charts ...ome of 27 inbred lines of maize. The research team...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2University of Phoenix Expands Advanced Degree Programs 3B Adds Ph D in Nursing and Educational Specialist Degrees 51246 1University of Phoenix Expands Advanced Degree Programs 3B Adds Ph D in Nursing and Educational Specialist Degrees 51246 2University of Phoenix Expands Advanced Degree Programs 3B Adds Ph D in Nursing and Educational Specialist Degrees 51246 3Nick Jonas Joins with Washington Nationals to Support Children with Diatbetes 51244 1Nick Jonas Joins with Washington Nationals to Support Children with Diatbetes 51244 2Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 51241 1Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 51241 2Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 51241 3Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 51241 4
...nder development could aid the treatment, and in s...wborn babies in intensive care. , By providing vit...e, the scanner avoids the need to move critically ...ich may involve sedating them and has a degree of ...used to diagnose and assess conditions such as bra...
...es, several motor molecules have to cooperate. Sci...and Interfaces in Potsdam have now developed a new...re sufficient for directed transport over centimet... load force, which is shared by the pulling motors... a highly nonlinear force-velocity relationship (P...
...inely inside the body and see -- at the level of t...ream. But in a series of experiments with genetica...e Howard Hughes Medical Institute (HHMI) at the Un... step toward realizing that vision by demonstratin...ly and see the immune system at work. , The new re...
Other Biology News:New brain scan technology could save babies' lives 2Marathon of nano-sprinters 2Marathon of nano-sprinters 3Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method 2Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method 3
...presents a major advance in liquid dispensing tech...obotic liquid handlers into the realm of the small...anging from 10mL to 2mL per well, the micro 10 has... dispensers. ,Features: , Never needs re-c...
Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
PerkinElmer Spectrum Beer's Law QUANT Quantitative Software, CD from PerkinElmer
... you to identify over 150 peptide modifications si...orms, protein subsets, and suppress false positive...ions and relationships easily. The software is ide... expression analysis for discovery research. The P...
Biology Products: